MiMedx Launches AMNIOFIX Thyroid Shields to Reduce Nerve Damage in Thyroidectomies — MiMedx Group, Inc.

Event summary

MiMedx launched AMNIOFIX Thyroid Shields on March 5, 2026, designed to protect the Recurrent Laryngeal Nerve (RLN) during thyroid surgery.
The product is a line extension of the company's AMNIOFIX dehydrated human amnion/chorion membrane (DHACM) allografts.
A retrospective study showed a 76% reduction in RLN damage at 24 hours postop when using AMNIOFIX compared to non-AMNIOFIX patients.
AMNIOFIX Thyroid Shields are shelf-stable for up to five years and are manufactured using the PURION process.

The big picture

MiMedx's launch of AMNIOFIX Thyroid Shields targets a critical unmet need in thyroid surgery, where nerve damage can lead to severe vocal impairment. The product's design to save intraoperative time and its proven efficacy in reducing RLN damage position it as a potential standard in endocrine surgical care. This expansion aligns with MiMedx's strategy to diversify its surgical product portfolio beyond wound care and burns.

What we're watching

Clinical Adoption: How quickly surgeons will integrate AMNIOFIX Thyroid Shields into standard thyroidectomy procedures.
Market Expansion: Whether MiMedx can leverage this product to expand its presence in the endocrine surgery market.
Competitive Response: The pace at which competitors may develop similar protective barriers for nerve and gland preservation.